Congenital hypothyroidism (CH), due to dyshormonogenesis, occurs due to defective thyroid hormone biosynthesis in a structurally normal gland, and causes include mutations in the reduced form of NAD phosphate (NADPH)-oxidase *DUOX2*, which generates the hydrogen peroxide (H~2~O~2~) required for the organification of iodide. *DUOX2* is contiguous with *DUOX1*, which encodes an additional thyroidal NADPH-oxidase on the long arm of chromosome 15, and their respective *DUOXA* maturation factor genes occupy the *DUOX* intergenic region \[Supplemental Fig. 1(A)\]. The DUOX1 and DUOX2 proteins exhibit 83% sequence homology; however, DUOX2 is thought to be the dominant isoenzyme in the thyroid, as evidenced by its higher thyroidal expression levels and the observations that human mutations in both *DUOX2* and *DUOXA2*, but not *DUOX1*, have been implicated in CH. Additionally, in murine models, only *DUOX2* loss of function is associated with hypothyroidism; thus, the role of DUOX1 in thyroid biology remains unclear ([@B1]).

*DUOX2* mutations usually cause transient CH or permanent CH with partial iodide organification defect. Permanent and transient CH may result from both mono- and biallelic mutations, and phenotypic heterogeneity may occur with similar mutations ([@B2]). The mechanisms modulating disease severity are unclear and may include genetic or epigenetic factors and environmental contributors, *e.g.*, iodine intake. Because DUOX1 also generates H~2~O~2~ in the thyroid, it has been suggested that this isoenzyme may undergo variable upregulation to compensate for the DUOX2 deficiency, although no naturally occurring *DUOX1* functional variants have hitherto been described.

We previously reported two Probands harboring a homozygous, known pathogenic nonsense mutation in *DUOX2* (p.R434\*), both of whom exhibited uncharacteristically severe CH ([@B3]). Whole-exome sequencing in this kindred detected digenicity for a homozygous essential splice site *DUOX1* mutation (c.1823-1G\>C) in affected individuals, found to be pathogenic *in vitro* and likely contributing to the phenotypic severity.

Materials and Methods {#s4}
=====================

All investigations were ethically approved and/or clinically indicated, being undertaken with patient or parental consent.

Biochemical measurements {#s5}
------------------------

Hormone measurements were made using local automated assays.

Molecular genetic studies {#s6}
-------------------------

Detailed methods for performing and analyzing data from whole-exome sequencing and Sanger sequencing of the *DUOX1* variant are provided in Supplemental Material.

*In vitro* characterization of the DUOX1 splice site mutation {#s7}
-------------------------------------------------------------

RNA extracted from peripheral leukocytes was reverse transcribed, and complementary DNA was polymerase chain reaction amplified using primers spanning translated exons 14--18, purified, and directly sequenced (Supplemental Material).

Results {#s8}
=======

Clinical and biochemical features {#s9}
---------------------------------

The patients' clinical details have previously been published ([@B3]) ([Fig. 1](#F1){ref-type="fig"}). Briefly, three patients with CH were born to consanguineous Turkish parents; the first (female) was diagnosed aged 6 months with thyrotropin (TSH) \>150 µU/mL \[reference range (RR) 0.5 to 6.3\] and FT4 0.42 ng/dL (RR 0.9 to 2.3), but subsequently died due to congenital heart disease. The second (female, P1) presented aged 6 months with growth retardation (height 56 cm, \<3rd centile, weight 5.6 kg, \<3rd centile), somnolence, and constipation. She had coarse facial features, macroglossia, and severe biochemical hypothyroidism \[TSH \>100 µU/mL (RR 0.5 to 6.3) and FT4 \<0.09 ng/dL (RR 0.9 to 2.3)\] and has severe learning difficulties aged 12 years. Thyroid ultrasound aged 3 years demonstrated a normally located thyroid gland (right lobe: 11 × 9 mm; left lobe: 13 × 8 mm), and more quantitative ultrasonography aged 11 years confirmed a normal thyroid volume (right lobe: 34 × 14 × 12 mm; left lobe: 32 × 13 × 14 mm; isthmus: 3.5 mm), although this may have been influenced by the fact that she was on levothyroxine treatment. Her younger brother (P2), who exhibited umbilical hernia, was diagnosed aged 8 days, with goitre and TSH \>100 µU/mL (RR 0.5 to 20). Treatment was commenced with 25 µg levothyroxine per day (10 µg/kg/d); however, aged 1 month, TSH remained elevated despite good treatment compliance, suggesting severe CH \[TSH 91 µU/mL (RR 0.5 to 9) and FT4 1.2 ng/dL (RR 0.9 to 2.3)\], and levothyroxine dose was rapidly increased to 50 µg/d. Thyroid ultrasonography demonstrated a normally located, diffusely hyperplastic gland. Both children ultimately required significant doses of [l]{.smallcaps}-thyroxine (87.5 µg, 1.9 micrograms/kg/d, P1 aged 12 years; 75 µg, 3.1 µg/kg/d, P2 aged 5.75 years). Their sister (S1) was unaffected aged 4 years \[TSH 1.7 µU/mL (RR 0.5 to 6.3); FT4 1.3 ng/dL (RR 0.9 to 2.3)\].

![Pedigree diagram summarizing clinical phenotype and genotype. Black: homozygotes for the *DUOX2* and *DUOX1* mutations; central black dot: heterozygotes for the two mutations. The degree of iodine deficiency on the spot urinary measurement is classified according to World Health Organization criteria. DUOX1 fs, DUOX1 p.Val607Aspfs\*43; het, heterozygous; hom, homozygous.](jc.2017-00529f1){#F1}

Their father was euthyroid \[TSH 1.7 µU/mL (RR 0.6 to 5.5); FT4 1.33 ng/dL (RR 0.9 to 2.3)\], and their mother, who had previously undergone thyroidectomy for autoimmune hyperthyroidism, was euthyroid on levothyroxine treatment \[TSH 0.27 µU/mL (RR 0.6 to 5.5); FT4 1.36 ng/dL (RR 0.9 to 2.3); anti--thyroid peroxidase antibodies 51 IU/mL (RR 0 to 35)\]. Her obstetric history also included two abortions and a hydatidiform mole. She had taken Propisyl for hyperthyroidism during her pregnancies with P2, and S1 but not P1.

Molecular genetic studies {#s10}
-------------------------

A previously described homozygous *DUOX2* nonsense mutation (c.1300C\>T, p. R434\*) had initially been identified in P1 and P2, for which their parents and unaffected sibling were heterozygous ([Fig. 1](#F1){ref-type="fig"}) ([@B3]). DNA was not available from the deceased sibling.

The severity of the CH prompted investigation for an additional genetic mutation using whole-exome sequencing in P1 and P2. In addition to coding regions, significant intronic sequences were covered using this technique, enabling detection of a homozygous essential splice site change in *DUOX1* (c.1823-1G\>C), at the intron 14/exon 15 boundary, validated by Sanger sequencing in both cases. This was absent from 400 ethnically matched control chromosomes and normal genome datasets \[dbSNP, Exome Aggregation Consortium, Cambridge, MA (URL: <http://exac.broadinstitute.org>), February 2017\]; both parents and S1 were heterozygous, confirming the segregation of the mutation with congenital hypothyroidism in the family ([Fig. 1](#F1){ref-type="fig"}). No additional mutations were detected in known causative CH genes.

*In vitro* confirmation of the pathogenicity of the DUOX1 splice site mutation {#s11}
------------------------------------------------------------------------------

In the heterozygotes, a wild-type DUOX1 fragment of expected size (622 bp) was amplified from peripheral blood mononuclear cells. In contrast, in the homozygotes, a higher molecular weight band was detected and sequencing confirmed a 40-bp insertion in the 3′ portion of intron 14, indicating the activation of a cryptic acceptor site in intron 14 \[r.(1823-40_1823-1ins; 1823-1G\>C)\] ([Fig. 2](#F2){ref-type="fig"}). This alternative splicing generates a frameshift and a stop codon in exon 15 (p.Val607Aspfs\*43) predicted to truncate DUOX1 within the transmembrane helices shortly after the peroxidase domain \[Supplemental Fig. 1(B)\]. In the heterozygotes, the high instability of this alternative splicing/nonsense transcript, derived from the mutant *DUOX1* allele, may have led to the preferential amplification of the correctly spliced wild-type transcript ([Fig. 2](#F2){ref-type="fig"}).

![Complementary DNA amplification and sequencing from homozygous and heterozygous family members, demonstrating aberrant splicing of *DUOX1*. The electropherogram of the complementary DNAs and transcript sizes of the different *DUOX1* variants detected in the family members are shown. Exons are numbered with the first translated exon as exon 1. P1, P2: children with CH and homozygous DUOX1 c.1823-1G\>C mutation. M, mother; F, father; S1, sister; all unaffected and heterozygous for the DUOX1 c.1823-1G\>C mutation.](jc.2017-00529f2){#F2}

Further biochemical evaluation {#s12}
------------------------------

Urine iodine measurements were not available at diagnosis, but subsequent spot measurements suggested mild (P2, 73.9 µg/L) to moderate (P1, 45.6 µg/L) iodine deficiency (RR 100 to 700 µg/L). Moderate iodine deficiency in association with double heterozygosity for *DUOX1* and *DUOX2* mutations (S1 and parents) did not result in hypothyroidism (urinary iodine: mother 39.2 µg/L; father 38.7 µg/L; S1 43.1 µg/L; RR 100 to 700 µg/L) ([Fig. 1](#F1){ref-type="fig"}).

Discussion {#s13}
==========

We report CH cases harboring a homozygous loss-of-function mutation in *DUOX1* (c.1823-1G\>C), inherited digenically with a homozygous *DUOX2* nonsense mutation (c.1300 C\>T, p. R434\*) ([@B3], [@B4]). The tertiary structure of DUOX1 and -2 is summarized in Supplemental Fig. 1(B); aberrant splicing of DUOX1 (c.1823-1G\>C) will generate a truncated protein (p.Val607Aspfs\*43) lacking the C-terminal flavin adenine dinucleotide and NADPH binding domains and cytosolic Ca^2+^ binding sites (EF-hand motifs) \[Supplemental Fig. 1(B)\].

*In vitro* evaluation of a similarly truncated DUOX1 isoenzyme comprising amino acids 1 to 593 alone abolished H~2~O~2~-generating activity ([@B5]). Moreover, similar truncations in the highly homologous DUOX2 \[p.Q686\*, p.R701\*, p.(G418fsX482);(IVS19-2A\>C), p.S965fsX994\] are associated with CH or severely impaired H~2~O~2~-generating activity *in vitro* ([@B4], [@B6], [@B7]). The c.1823-1G\>C mutation would be predicted to generate a nonfunctional DUOX1 enzyme, and its digenic inheritance alongside the homozygous DUOX2 p.R434\* will likely result in complete absence of functional DUOX isoenzyme in our patients.

It has been speculated that DUOX1 upregulation in the context of DUOX2 loss of function may at least partially compensate for defective H~2~O~2~ production. In support of this notion, the majority of reported biallelic *DUOX2* mutations, which are known to truncate the protein before the H~2~O~2~-generating domains, cause transient or mild permanent CH, despite presumably abrogating DUOX2 activity completely ([@B8], [@B9]) ([Table 1](#T1){ref-type="table"}). Direct comparison of biochemistry from reported cases with measurements made in our kindred is precluded by lack of T4 measurement in P2, and the fact that CH was diagnosed in P1 and her deceased sibling aged 6 months, rather than neonatally. However, in cases with biallelic truncating mutations, there is a broad spectrum of FT4 measurements at diagnosis, ranging from undetectable to 1.5 ng/dL, and partial iodide organification defects in all except one evaluated case. As well as mandating that other enzymes besides DUOX2 are capable of thyroidal H~2~O~2~ synthesis, this observation suggests heterogeneity in the efficiency of this compensatory process, likely due to either genetic or environmental modulators. Digenic, homozygous *DUOX2* and *DUOX1* mutations in our patients are associated with uncharacteristically severe CH; therefore, we speculate that inability of DUOX1 to compensate for defective H~2~O~2~ production may be contributing to disease severity. Unfortunately, the close chromosomal proximity of *DUOX1* and *DUOX2* mandates cosegregation of the two mutations, precluding evaluation of their individual contributions.

###### 

**Table Summarizing Clinical Phenotype and Genotype Information for Published Cases Harboring Biallelic, Confirmed Truncating Mutations in DUOX2**

  **Reference**                      **Case**                                                           **DUOX2 Mutation**                                                 **bsTSH (mU/L)**                           **vTSH (mU/L)**                            **FT4 (ng/dL)**                             **US**   **KClO~4~** **(%)**   **CH Duration**
  ---------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------- -------- --------------------- -----------------
  Current cases                      P1                                                                 p.\[R434\*\];\[R434\*\]                                            ---                                        \>100[*^a^*](#t1n1){ref-type="table-fn"}   \<0.09[*^a^*](#t1n1){ref-type="table-fn"}   ---      ---                   P
  P2                                 p.\[R434\*\];\[R434\*\]                                            ---                                                                \>100[*^b^*](#t1n2){ref-type="table-fn"}   ---                                        G                                           ---      P                     
  Nicholas *et al.*, 2016 ([@B10])   1                                                                  p.\[ L1028Afs\*3\];\[ L1028Afs\*3\]                                ---                                        55                                         ---                                         N                              ---
  Tan *et al.*, 2016 ([@B11])        2                                                                  p.\[K530\*\];\[K530\*\]                                            14.76                                      86.06                                      0.76                                        G        ---                   T
                                     3                                                                  p.\[K530\*\];\[K530\*\]                                            111.45                                     \>100                                      \<0.4                                       N        ---                   T
                                     4                                                                  p.\[K530\*\];\[K530\*\]                                            20.25                                      \>100                                      \<0.4                                       G        ---                   T
                                     5                                                                  p.\[K530\*\];\[K530\*\]                                            122.66                                     23.9                                       0.92                                        N        ---                   MP
                                     6                                                                  p.\[K530\*\];\[Q202Rfs\*93\]                                       9.3                                        \>100                                      \<0.4                                       G        ---                   T
                                     7                                                                  c.647-656del10ins15/p.K530\*                                       54.64                                      92.38                                      0.60                                        G        ---                   MP/T
                                     8                                                                  p.\[K530\*\];\[K530\*\]                                            14.05                                      9.58                                       0.92                                        G        ---                   T
                                     9                                                                  p.\[K530\*\];\[K1174Sfs\*12\]                                      11.88                                      \>100                                      0.49                                        N        ---                   ---
                                     10                                                                 p.\[R701\*\];\[K530\*\]                                            46.17                                      \>100                                      0.43                                        G        ---                   MP/T
                                     11                                                                 p.\[Q202Tfs\*99\];\[K530\*\]                                       14.47                                      12.1                                       1.03                                        G        ---                   ---
  Fu *et al.*, 2016 ([@B9])          12                                                                 p.\[K530\*\];\[K530\*\]                                            \>8                                        \>100                                      0.17                                        N        ---                   T
  13                                 p.\[L1114Sfs\*56\];\[K530\*\][*^c^*](#t1n3){ref-type="table-fn"}   \>8                                                                \>100                                      0.32                                       N                                           ---      T                     
  Fu *et al.*, 2015 ([@B12])         14                                                                 p.\[L1114Sfs\*56\];\[K530\*\][*^c^*](#t1n3){ref-type="table-fn"}   \>8                                        \>100                                      0.32                                        N        ---                   T
  15                                 p.\[L1114Sfs\*56;W301C\];\[K530\*\]                                \>8                                                                \>100                                      0.63                                       H                                           ---      P                     
  Muzza *et al.*, 2014 ([@B2])       16                                                                 p.\[Q202Tfs\*99\];\[T522Pfs\*64\]                                  18                                         180                                        ---                                         ---      57                    P
  17                                 p.\[Q202Tfs\*99\];\[T522Pfs\*64\]                                  21                                                                 130                                        ---                                        ---                                         66       P                     
  Maruo *et al.*, 2008 ([@B8])       18                                                                 p.\[L479Sfs\*2\];\[K628Rfs\*10\]                                   36.9                                       95.4                                       0.43                                        G        ---                   T
  19                                 p.\[L479Sfs\*2\];\[K628Rfs\*10\]                                   21.4                                                               233                                        0.19                                       G                                           ---      T                     
  20                                 p.\[L479Sfs\*2\];\[K628Rfs\*10\]                                   18.5                                                               150                                        0.53                                       G                                           ---      T                     
  21                                 p.\[L479Sfs\*2\];\[K628Rfs\*10\]                                   10                                                                 25.7                                       1.5                                        G                                           ---      T                     
  Varela *et al.*, 2006 ([@B6])      22                                                                 p.\[G418Efs\*64\];c.\[2655-2A\>C\]                                 ---                                        \>100                                      \<1[*^d^*](#t1n4){ref-type="table-fn"}      G        60                    P
  23                                 p.\[G418Efs\*64\];c.\[2655-2A\>C\]                                 ---                                                                \>100                                      0.8[*^d^*](#t1n4){ref-type="table-fn"}     G                                           68       P                     
  Moreno *et al.*, 2002 ([@B4])      24                                                                 p.\[R434\*\];\[R434\*\]                                            \>50                                       1400                                       0.07                                        ---      100                   P

Abbreviations: bsTSH, blood spot screening TSH; G, goiter; H, hypoplastic; KClO~4~, perchlorate discharge; MP, mild permanent; N, normal; P, permanent; T, transient; US, ultrasound; vTSH, venous confirmatory TSH.

Biochemistry aged 6 months (P1).

Biochemistry aged 8 days (P2).

Compound heterozygosity assumed.

Total T4, μg/dL, normal range 5.98 to 13.9, measured aged 8 months (case 22) and 1 month (case 23). Normal ranges: FT4 ng/dL: Moreno *et al*., 0.9 to 2.3; Fu *et al*., 0.9 to 1.7; Maruo *et al*., 0.97 to 1.7; Tan *et al*., 0.9 to 2.28.

Urinary iodine was not measured contemporaneously with CH diagnosis in our kindred, and subsequent spot measurements did reveal mild--moderate iodine deficiency across the family, for which we cannot exclude a phenotypic contribution. Indeed, high dietary iodine intake in Japan is postulated to mitigate CH associated with DUOX2 mutations, accounting for the high frequency of transient CH in Japanese cases harboring biallelic mutations ([Table 1](#T1){ref-type="table"}). However, individuals in our kindred who were digenic for heterozygous *DUOX1* and *DUOX2* mutations remained euthyroid, despite moderate iodine deficiency, supporting a digenic, rather than environmental cause for the severe phenotype in the homozygous offspring.

It is noteworthy that the only other reported case harboring the homozygous *DUOX2* p.R434\* mutation (also Turkish) is unique in manifesting both total iodide organification defect and uncharacteristically severe CH. Although the disease severity in both kindreds could reflect an intrinsic characteristic of the very proximal DUOX2 p.R434\* mutation, this mutation is likely to be functionally identical to the Q202TfsX99, K530\*, and T522PfsX64 truncating mutations, which will also truncate DUOX2 within the peroxidase-like domain before the first transmembrane region. Cases harboring such biallelic mutations have been associated with partial iodide organification defect and variable disease trajectory, including transient CH, suggesting that factors other than the p.R434\* DUOX2 mutation itself are contributing to disease severity ([@B6], [@B8], [@B9]) ([Table 1](#T1){ref-type="table"}). Mutations in coding regions and intron--exon boundaries of *DUOX1* were excluded in the reported p.R434\* mutation case, which argues against digenic inheritance of the same *DUOX1* mutation as a founder effect in the Turkish population. However, oligogenic variants in other known hitherto undiscovered CH-associated genes (including the noncoding regions of *DUOX1*) may be contributing to disease severity. Alternative phenotypic modulators could include polygenic factors specific to the Turkish ethnic background, or environmental iodine deficiency, because iodine status was not evaluated ([@B4]). No DUOX1-sequencing results are reported for other cases with permanent CH associated with biallelic truncating *DUOX2* mutations listed in [Table 1](#T1){ref-type="table"}, although variants in other CH-associated genes were occasionally sought ([@B2], [@B6], [@B9], [@B10]).

In the wider CH context, next-generation sequencing technologies are elucidating a role for oligogenicity in disease pathogenesis ([@B10]). We describe the first human cases with digenic *DUOX* mutations causing complete DUOX isoenzyme deficiency in the context of likely iodine deficiency. These individuals manifest severe CH, suggesting failure to compensate for defective thyroid H~2~O~2~ synthesis. Although limited subphenotype information prevents definitive ascertainment of the relative roles of the two mutations in the thyroid dysfunction, we hypothesize that inability of DUOX1 to compensate for DUOX2 deficiency contributes to disease severity in this kindred. Further studies are required to interrogate the role of upregulation of DUOX1 and alternative H~2~O~2~-producing enzymes in DUOX2-deficient cases and the contribution of variants in these genes to the phenotypic heterogeneity associated with *DUOX2* mutations.

Abbreviations: CHcongenital hypothyroidismNADPHreduced form of NAD phosphateRRreference rangeTSHthyrotropin.
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